Kymera Therapeutics Inc
Veridion Score
Composite trend over time
Why is KYMR moving today?
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for KYMR.
KYMR insider activity
Kymera Therapeutics Inc
7 insiders bought in the last 90 days
Net selling: -$340.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-07 | Mainolfi Nello | Insider | sell | $119.00 | 50,000 | 666,568 | $6.0M | SEC Form 4 |
| 2026-07-07 | 2026-07-07 | Mainolfi Nello | Insider | buy | $2.08 | 50,000 | 716,568 | $104K | SEC Form 4 |
| 2026-07-02 | 2026-07-01 | Goodman Noah | Insider | sell | $114.29 | 3,389 | 47,179 | $387K | SEC Form 4 |
| 2026-07-02 | 2026-07-01 | Mainolfi Nello | Insider | sell | $116.56 | 3,336 | 666,568 | $389K | SEC Form 4 |
| 2026-07-02 | 2026-07-01 | Mainolfi Nello | Insider | sell | $115.69 | 44,050 | 669,904 | $5.1M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 163 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moKYMR contract awards, year to date.
Public federal awards linked to this ticker.
KYMR lobbying filings, year to date.
Registered lobbying filings matched to Kymera Therapeutics Inc.